Download presentation
Presentation is loading. Please wait.
Published byBrett Franklin Modified over 9 years ago
1
Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action
2
Process 1. Identification of issues 2. Country experiences and situation sharing 3. Identification of Key Actions 4. Moving Forward
3
Key Issues 1. Artemisinin monotherapy 2. Cross border issues on trade 3. Supply systems: implications beyond stock outs 4. Funding Commitments
4
Key Actions 1. Artemisinin monotherapy High level action/s: a) Withdrawal of monotherapies including action for trade Country level actions a) Transition mechanisms from monotherapy to combined formulations b) Ensuring access and availability of AT
5
Key Actions 2. Cross –border issues on trade, counterfeits and Substandard medicines High Level Action a) Common regulatory framework Country level actions a) Capacity strengthening for regulatory authorities: minimum level of standards b) Post-marketing surveillance and pharmacovigilance systems
6
Key Actions 3. Supply systems: implications beyond stock outs High Level Action a) Regional Drug Facility: standard formulations, prices (?) Country level actions a) Securing the public sector supply b) Capacity building
7
Key Actions 3. Funding Commitments a) Government and donor commitments
8
Ways Forward 1. Policy Briefs and Call for Action 2. Guideline for actions at country level 3. Streamlining capacity building in ongoing programs 4. Measuring action ( indicators)
9
Thank You
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.